Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genmab A (GNMSF) Research & Development (2024 - 2025)

Historic Research & Development for Genmab A (GNMSF) over the last 2 years, with Q4 2025 value amounting to $1.1 billion.

  • Genmab A's Research & Development fell 5584.63% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1606.0, marking a year-over-year decrease of 10000.01%. This contributed to the annual value of -$1606.0 for FY2025, which is 10000.01% down from last year.
  • As of Q4 2025, Genmab A's Research & Development stood at $1.1 billion, which was down 5584.63% from -$357.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Research & Development registered a high of $2.4 billion during Q4 2024, and its lowest value of -$364.0 million during Q2 2025.